<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic kidney disease resulting from atherosclerotic renal artery stenosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic kidney disease resulting from atherosclerotic renal artery stenosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic kidney disease resulting from atherosclerotic renal artery stenosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Textor, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Elliott, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Many but not all patients with atherosclerotic renal artery stenosis have chronic kidney disease (CKD) that is primarily due to a reduction in blood flow induced by the stenosis. A fall in blood flow and glomerular filtration rate (GFR) in one of two kidneys often results in compensatory increases in the "contralateral kidney." Thus, clinically progressive CKD as reflected by increased serum creatinine generally occurs when the stenosis threatens the entire kidney mass. Patients with CKD resulting from atherosclerotic renal artery stenosis usually have high-grade stenosis of both renal arteries or stenosis to a solitary functioning kidney.</p><p>However, renal artery stenosis may be an "incidental" finding in patients who have CKD that is caused by a separate disorder (eg, diabetic nephropathy). It can be difficult to distinguish between patients whose disease is induced by renal artery stenosis and those who have an alternative cause of CKD.</p><p>Ischemic nephropathy is discussed in this topic. Determining which hypertensive patients to evaluate for renal artery stenosis, establishing the diagnosis of renal artery stenosis, and treatment of patients with unilateral or bilateral atherosclerotic renal artery stenosis are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3834.html" rel="external">"Treatment of unilateral atherosclerotic renal artery stenosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney"</a>.)</p><p></p><p>In addition, the diagnosis and treatment of fibromuscular dysplasia are discussed in other topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3874.html" rel="external">"Clinical manifestations and diagnosis of fibromuscular dysplasia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3826.html" rel="external">"Treatment of fibromuscular dysplasia of the renal arteries"</a>.)</p><p></p><p class="headingAnchor" id="H4586586"><span class="h1">DEFINITION AND TERMINOLOGY</span><span class="headingEndMark"> — </span>CKD that results from atherosclerotic renal artery stenosis is frequently called "ischemic nephropathy" [<a href="#rid1">1-4</a>]. Broadly speaking, "ischemic nephropathy" could refer to a reduction in glomerular filtration rate (GFR) produced by any cause of diminished renal blood flow. In principle, this could include ischemic acute tubular necrosis, intrarenal arterial or capillary obstruction due to vasculitis, coagulation or hemolytic disorders (such as a thrombotic microangiopathy or sickle cell disease).</p><p>However, the term ischemic nephropathy is most commonly applied in patients who have CKD due to partial or complete obstruction of one or more extrarenal arteries [<a href="#rid2">2</a>], usually in patients with atherosclerotic disease. Thus, for the purposes of this review, ischemic nephropathy refers to the progressive loss of GFR resulting from atherosclerotic renal artery stenosis.</p><p>Although kidney injury can develop in any kidney or kidney region beyond a critically stenotic artery, the injury may not be clinically apparent, largely due to compensatory function of the unaffected contralateral kidney. As noted above, clinically apparent or progressive disease (marked by an increase in the serum creatinine) occurs primarily when the stenosis threatens the entire kidney mass. Hence, patients who are diagnosed with ischemic nephropathy usually have high-grade stenosis of both renal arteries or stenosis to a solitary functioning kidney.</p><p class="headingAnchor" id="H4587470"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Loss of kidney function in renovascular disease can result from a usually reversible consequence of antihypertensive therapy or can reflect progressive narrowing of the renal arteries and/or progressive intrinsic kidney disease. Studies in human subjects demonstrate that, despite a moderate reduction in kidney perfusion pressure (up to 40 percent) and in renal blood flow (mean 30 percent), glomerular filtration is reduced but tissue oxygenation within the kidney cortex and medulla can adapt without the development of severe hypoxia [<a href="#rid5">5,6</a>]. As a corollary, many such patients can be treated with medical therapy without progressive loss of function or irreversible fibrosis, sometimes for many years [<a href="#rid7">7,8</a>].</p><p>However, more advanced vascular occlusion, corresponding to a 70 to 80 percent narrowing of the renal artery [<a href="#rid9">9,10</a>], leads to demonstrable cortical hypoxia that can be measured by blood oxygen level dependent magnetic resonance (BOLD-MR) [<a href="#rid11">11,12</a>]. In animal studies, this tissue hypoxia produces rarefaction of microvessels, as well as activation of inflammatory and oxidative pathways that lead to interstitial fibrosis [<a href="#rid13">13</a>]. Several studies suggest that these changes also take place as a result of renal artery stenosis in human kidneys. In one study, for example, inflammatory markers sampled from renal veins of stenotic kidneys correlated strongly with the degree of hypoxia (as measured by BOLD-MR), particularly after correction of the stenosis with angioplasty [<a href="#rid14">14</a>]. Inflammatory changes and fibrosis are also evident in human "pressor" kidneys that were removed to treat hypertension in patients with a totally occluded renal artery [<a href="#rid15">15</a>].</p><p>Although vascular occlusion can initiate these processes, long-standing parenchymal injury characterized by inflammation and fibrosis eventually becomes an irreversible process. At some point, restoring renal blood flow provides no recovery of kidney function or clinical benefit.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Ischemic nephropathy is an increasingly recognized disorder [<a href="#rid2">2,16-21</a>]. However, few prospective studies have examined the incidence or progression of CKD among patients with renal artery stenosis. In addition, renal artery revascularization among patients in these studies infrequently produced a meaningful recovery of kidney function, which would have supported the diagnosis [<a href="#rid22">22</a>]. Thus, the true incidence and prevalence of ischemic nephropathy is unclear.</p><p>Various studies have reported that 5 to 22 percent of patients 50 years or older who have advanced CKD have some degree of renal artery stenosis [<a href="#rid17">17,23-28</a>]. However, the renovascular lesions may have been "incidental" in some if not many of these patients. The following examples illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>The natural history of ischemic nephropathy was evaluated in a study of 51 patients with angiographically confirmed bilateral renal artery stenosis (defined as 90 percent or greater stenosis to one kidney and 50 percent or greater to the contralateral kidney) who were followed for up to five years [<a href="#rid28">28</a>]. The median estimated glomerular filtration rate (eGFR) declined from 39 to 24 mL/min per 1.73 m<sup>2</sup> over five years, and 12 percent of patients developed end-stage kidney disease (ESKD), although these individuals had advanced disease at baseline (eGFR 25 mL/min per 1.73 m<sup>2</sup>). For various reasons, no patient was revascularized (eg, patient or clinician preference, "unsalvageable" kidneys, patient not suitable for the procedure, or lesion not amenable to the procedure), suggesting that findings may not be applicable to some patients diagnosed with ischemic nephropathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, progression of kidney disease may be infrequent in those incidentally discovered to have moderate renal artery stenosis. In a study of 593 patients who underwent angiography for peripheral artery disease, 397 had interpretable "drive by" renal angiograms [<a href="#rid27">27</a>]. Of these, 126 had at least moderate (more than a 50 percent) stenosis of one or more renal arteries (38 had bilateral stenosis or stenosis to a single functioning kidney). The mean eGFR among these patients was 58 mL/min per 1.73 m<sup>2</sup>. After 10 years, kidney function remained stable and no patient developed ESKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal artery stenosis is a common finding among patients initiating dialysis. This was shown in a study of 80 consecutive patients initiating hemodialysis at a single center [<a href="#rid26">26</a>]. Of the 49 patients who agreed to undergo computerized tomography angiography (CTA), bilateral renal artery stenosis (defined as a 50 percent or greater diameter reduction) was present in eight patients (16 percent). Three of these patients were not known to have renovascular disease and initiated dialysis with unexplained kidney failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two randomized trials comparing percutaneous transluminal renal angioplasty with medical therapy alone primarily enrolled patients with CKD at baseline [<a href="#rid7">7,29</a>], although most patients had unilateral rather than bilateral stenosis. The incidence of kidney endpoints in these trials (defined either as a 20 percent reduction in creatinine clearance or as a composite of acute kidney injury, ESKD, or kidney death) was 19 percent during two to five years of follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 95 patients undergoing surgical revascularization of totally occluded renal arteries, 49 percent had improved kidney function, including some with ESKD who became independent from dialysis [<a href="#rid30">30</a>]. In a study of 146 patients who had renal artery stenting, only 45 percent experienced stabilization or improvement of their kidney function at five years [<a href="#rid31">31</a>]. Numerous case reports and selected observational series indicate that patients with rapidly progressive kidney failure, usually associated with severe hypertension, can recover kidney function [<a href="#rid32">32-34</a>]. Such reports provide de facto clinical evidence that some but not all atherosclerotic renovascular disease does produce hemodynamic limitations to kidney function that can improve after revascularization. Those individuals whose kidney function improves measurably after revascularization have improved long-term survival as compared with those whose function deteriorates or remains unchanged [<a href="#rid35">35</a>].</p><p></p><p>The epidemiology of renal artery stenosis in general is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with ischemic nephropathy typically present as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>A persistent and progressive reduction in glomerular filtration rate (GFR) (ie, CKD).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lack of evidence supporting an alternative cause of kidney disease, such as an abnormal urinalysis, proteinuria, a paraprotein, or use of a nephrotoxic drug. (See  <a class="medical medical_review" href="/d/html/7188.html" rel="external">"Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Findings that suggest the presence of renovascular disease, for example (<a class="graphic graphic_table graphicRef56130" href="/d/graphic/56130.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe hypertension that may be treatment resistant. However, a few patients with ischemic nephropathy are normotensive, which may be due in part to a reduced cardiac output [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An acute rise in serum creatinine following the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). This usually, but not invariably, resolves after withdrawal of the drug.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant variability of serum creatinine concentration that may be due to changes in volume status [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent episodes of flash pulmonary edema and/or refractory heart failure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deterioration of kidney function after placement of an endovascular aortic stent graft.</p><p></p><p>In addition, risk factors for atherosclerotic disease are often present, such as hyperlipidemia, cigarette smoking, and age greater than 50 years. Patients with ischemic nephropathy frequently have coronary artery disease or peripheral arterial disease in other vascular beds. (See  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension", section on 'Incidental lesions'</a>.)</p><p>In patients with renal artery stenosis, there is a reasonable correlation between estimated glomerular filtration rate (eGFR) and measured GFR (correlation coefficients range from 0.7 to 0.85 depending upon the estimating equation used) [<a href="#rid37">37</a>]. However, changes in measured GFR over time are not always accurately identified by temporal changes in eGFR. During approximately one year of follow-up, the direction of GFR change predicted by estimating equations was discordant with the true direction of GFR change in 28 to 40 percent of patients (depending upon the equation used). This may reflect changes in GFR in both the treated kidney and reversal of compensatory hypertrophy in the contralateral kidney [<a href="#rid14">14</a>]. It may also be related to exaggerated variability of the serum creatinine caused by changes in extracellular fluid volume or systemic blood pressure superimposed upon partial vascular occlusion.</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>In patients with clinical manifestations of ischemic nephropathy (see <a class="local">'Clinical manifestations'</a> above), a presumptive diagnosis of ischemic nephropathy can be made if there is radiologic documentation of significant stenosis (usually more than 70 percent luminal occlusion) of both renal arteries or of one renal artery to a solitary functioning kidney. Indications and options for radiographic imaging of renal artery stenosis and the interpretation of these tests are presented elsewhere. In general, these imaging tests to diagnose renal artery stenosis are warranted if a corrective procedure would be performed should significant renovascular lesions be identified and should the kidneys appear to be salvageable. (See  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>.)</p><p>As a practical matter, there are two diagnostic elements to consider in patients who could have ischemic nephropathy; these diagnostic elements can impact treatment decisions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is the vascular occlusive disease posing critical hemodynamic limitation to kidney function?</strong> In general, luminal occlusion of at least 60 to 75 percent is required to limit blood flow and reduce perfusion pressure [<a href="#rid38">38,39</a>]. This degree of stenosis is usually associated with a measurable translesional pressure gradient of 10 to 15 mmHg [<a href="#rid40">40,41</a>]. Doppler ultrasound criteria conventionally require peak systolic velocities above 180 to 200 cm/sec to identify more than 60 percent luminal occlusion that is verified by pressure gradients [<a href="#rid40">40</a>]. Identifiable levels of cortical hypoxia (measured by blood oxygen level dependent magnetic resonance [BOLD-MR]) are usually associated with translesional velocities above 385 cm/sec [<a href="#rid11">11</a>] or reduction of single kidney glomerular filtration rate (GFR) in the range of 20 to 25 mL/min [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is the condition of the kidneys such that restoring renal blood flow is likely to benefit function?</strong> The condition of the kidneys can be assessed by considering the renal resistive index, the six-month trajectory of kidney function, and the size of the kidneys, or by performing a kidney biopsy (which is not usually done). None of these factors predict the outcome of revascularization with certainty. Improved and validated methods to evaluate the salvageability of kidney function in this disorder are sorely needed. Some that have been proposed are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal resistive index – Some studies indicate that elevated resistive indices in segmental vessels (above 0.80) measured by duplex ultrasound denote poor prognosis for kidney function recovery [<a href="#rid42">42</a>] while a low resistive index is a favorable sign [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trajectory of kidney function – The most consistent predictor of good recovery of kidney function after revascularization has been a recent deterioration of kidney function (ie, in the prior six to twelve months) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney size – Very small kidneys (less than 7 cm in longest diameter) are usually considered unlikely to recover after revascularization [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney biopsy – Previous studies suggest that biopsy demonstrating preexisting atheroembolic changes and interstitial fibrosis indicate a limited potential for recovery [<a href="#rid46">46</a>]. Biopsies are not usually performed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comparison of kidney morphology with kidney function – Some investigators recommend assessing morphologic parameters, such as renal parenchymal volume and cortical thickness with MRI, and comparing these parameters with kidney function measured by radionuclide scanning [<a href="#rid47">47,48</a>]. In a stenotic kidney, apparently normal morphology combined with reduced function may indicate a "hibernating kidney" that could be salvaged with revascularization. In some cases, parenchymal viability is likely maintained by collateral vessels insufficient to support glomerular filtration [<a href="#rid49">49</a>].</p><p></p><p>A definitive diagnosis is not usually made before revascularization. In practice, confirmation of the diagnosis is based upon stabilization or improvement of the GFR after successful revascularization.</p><p>While endovascular or surgical revascularization can restore vessel patency and improve blood flow, these procedures are potentially hazardous, particularly within the severely diseased aorta. Potential complications of revascularization include atheroembolic kidney disease and contrast nephropathy. In addition, as noted above, restoring blood flow alone may not reverse the kidney disease. Hence, the clinical decision to pursue extensive diagnostic studies and renal artery intervention should weigh renal salvageability against comorbid diseases and risk.</p><p class="headingAnchor" id="H6"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Patients at risk for bilateral renal artery stenosis are also at risk for other disorders that can present with similar clinical findings but cannot be corrected by surgery or angioplasty; these include hypertensive nephrosclerosis and atheroembolic kidney disease.</p><p>Hypertensive nephrosclerosis has a similar clinical presentation to chronic ischemic kidney disease: hypertension, slowly progressive CKD, an unremarkable urine sediment, and possible evidence of atherosclerotic vascular disease. It is only the presence of the clinical clues described above that suggests the presence of renovascular disease. (See  <a class="medical medical_review" href="/d/html/3824.html" rel="external">"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis"</a>.)</p><p>Atheroembolic kidney disease can be precipitated by aortic manipulation or can occur spontaneously. It can generally be distinguished from bilateral renal artery stenosis or nephrosclerosis by an abrupt decline in kidney function, evidence of extrarenal emboli (manifested by digital gangrene, livedo reticularis, or abdominal pain), and the transient presence of hypocomplementemia, eosinophilia, and/or eosinophiluria. Arteriography is contraindicated in this setting since there is a high risk of inducing further embolization. (See  <a class="medical medical_review" href="/d/html/7182.html" rel="external">"Clinical presentation, evaluation, and treatment of renal atheroemboli"</a> and  <a class="medical medical_review" href="/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"</a>.)</p><p class="headingAnchor" id="H4590154"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Once a presumptive diagnosis of ischemic nephropathy is made, the management issues are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients should receive medical therapy to control their hypertension in addition to routine CKD care and surveillance. Since these individuals have atherosclerotic cardiovascular disease, they should also be aggressively treated for secondary prevention of cardiovascular morbidity with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, statins, cessation of smoking, and, in patients with diabetes, glycemic control. (See  <a class="medical medical_review" href="/d/html/7172.html" rel="external">"Overview of the management of chronic kidney disease in adults"</a> and  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to medical therapy and risk factor reduction, <strong>some but not all patients should undergo revascularization</strong>, depending upon the hemodynamic severity and likely recoverability of kidney function, as discussed above (usually achieved with percutaneous transluminal renal angioplasty plus a stent or, in selected patients, with surgery). This issue and the corresponding treatment recommendations are discussed elsewhere in detail. (See  <a class="medical medical_review" href="/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney", section on 'Treatment'</a>.)</p><p></p><p>Results from studies of selected patients with ischemic nephropathy subjected to revascularization suggest that 25 to 30 percent will recover kidney function to a meaningful degree, sometimes avoiding progression to end-stage kidney disease (ESKD) and/or the need for kidney replacement therapy. Approximately 50 percent will have little immediate change in kidney function but will "stabilize," whereas approximately 20 percent will have a progressive deterioration of kidney function, sometimes related to the procedure [<a href="#rid2">2</a>]. Prospective trials such as CORAL reported fewer complications in experienced centers (2 to 5 percent) than previously reported (9 percent) [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Many but not all patients with atherosclerotic renal artery stenosis have chronic kidney disease (CKD) that is primarily due to a reduction in blood flow induced by the stenosis. In general, clinically apparent or progressive CKD (marked by an increase in the serum creatinine) occurs when the stenosis threatens the entire kidney mass. Hence, patients with CKD resulting from atherosclerotic renal artery stenosis usually have high-grade stenosis of both renal arteries or stenosis to a solitary functioning kidney. However, renal artery stenosis may be an "incidental" finding in patients who have CKD that is caused by a separate disorder (eg, diabetic nephropathy). It can be difficult to distinguish between patients whose disease is induced by renal artery stenosis and those who have an alternative cause of CKD. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CKD that results from atherosclerotic renal artery stenosis is frequently called ischemic nephropathy. Broadly speaking, "ischemic nephropathy" can refer to a reduction in glomerular filtration rate (GFR) produced by any cause of diminished renal blood flow. However, the term ischemic nephropathy is most commonly applied in patients who have CKD due to partial or complete obstruction of one or more extrarenal arteries, usually in patients with atherosclerotic disease. (See <a class="local">'Definition and terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite a moderate reduction in renal perfusion pressure (up to 40 percent) and in renal blood flow (mean 30 percent), glomerular filtration is reduced but tissue oxygenation within the kidney cortex and medulla can adapt without the development of severe hypoxia. However, more advanced vascular occlusion, corresponding to a 70 to 80 percent narrowing of the renal artery, leads to demonstrable cortical hypoxia. In animal studies, this tissue hypoxia produces rarefaction of microvessels, as well as activation of inflammatory and oxidative pathways that lead to interstitial fibrosis. Although vascular occlusion can initiate these processes, long-standing parenchymal injury characterized by inflammation and fibrosis eventually becomes an irreversible process. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ischemic nephropathy typically present as follows (see <a class="local">'Clinical manifestations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A persistent and progressive reduction in GFR (ie, CKD).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of evidence supporting an alternative cause of kidney disease, such as an abnormal urinalysis, proteinuria, a paraprotein, or use of a nephrotoxic drug.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Findings that suggest the presence of renovascular disease (<a class="graphic graphic_table graphicRef56130" href="/d/graphic/56130.html" rel="external">table 1</a>), for example: severe hypertension that may be treatment resistant, an acute rise in serum creatinine following the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), significant variability of serum creatinine concentration that may be due to changes in volume status, recurrent episodes of flash pulmonary edema and/or refractory heart failure, and deterioration of kidney function after placement of an endovascular aortic stent graft.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition, risk factors for atherosclerotic disease are often present, such as hyperlipidemia, cigarette smoking, and age greater than 50 years. Patients with ischemic nephropathy frequently have coronary artery disease or peripheral arterial disease in other vascular beds.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with clinical manifestations of ischemic nephropathy, a presumptive diagnosis of ischemic nephropathy can be made if there is radiologic documentation of significant stenosis of both renal arteries or of one renal artery to a solitary functioning kidney. As a practical matter, there are two diagnostic elements to consider in patients who could have ischemic nephropathy; these diagnostic elements can impact treatment decisions (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Is the vascular occlusive disease posing critical hemodynamic limitation to kidney function? In general, luminal occlusion of at least 60 to 75 percent is required to limit blood flow and reduce perfusion pressure. This degree of stenosis is usually associated with a measurable translesional pressure gradient of 10 to 15 mmHg. Doppler ultrasound criteria conventionally require peak systolic velocities above 180 to 200 cm/sec to identify more than 60 percent luminal occlusion that is verified by pressure gradients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Is the condition of the kidneys such that restoring renal blood flow is likely to benefit function? The condition of the kidneys can be assessed by considering the renal resistive index, the six-month trajectory of kidney function, and the size of the kidneys, or by performing a kidney biopsy (which is not usually done). None of these factors predict the outcome of revascularization with certainty.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A definitive diagnosis is not usually made. In practice, confirmation of the diagnosis is based upon stabilization or improvement of the GFR after successful revascularization. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients at risk for bilateral renal artery stenosis are also at risk for other disorders that can present with similar clinical findings but cannot be corrected by surgery or angioplasty, including hypertensive nephrosclerosis and atheroembolic kidney disease. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once a presumptive diagnosis of ischemic nephropathy is made, patients should receive medical therapy to control their hypertension in addition to routine CKD care and surveillance. Since these individuals have atherosclerotic cardiovascular disease, they should also be aggressively treated for secondary prevention of cardiovascular morbidity with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, statins, cessation of smoking, and, in patients with diabetes, glycemic control. In addition to medical therapy and risk factor reduction, <strong>some but not all patients should undergo revascularization</strong> (usually achieved with percutaneous transluminal renal angioplasty plus a stent or, in selected patients, with surgery). This issue and the corresponding treatment recommendations are discussed elsewhere in detail. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/3836.html" rel="external">"Treatment of bilateral atherosclerotic renal artery stenosis or stenosis to a solitary functioning kidney", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H2430691303"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Lionel U Mailloux, MD, FACP, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hicks CW, Clark TWI, Cooper CJ, et al. Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. Am J Kidney Dis 2022; 79:289.</a></li><li><a class="nounderline abstract_t">Textor SC, Misra S, Oderich GS. Percutaneous revascularization for ischemic nephropathy: the past, present, and future. Kidney Int 2013; 83:28.</a></li><li><a class="nounderline abstract_t">Adamczak M, Wiecek A. Ischemic nephropathy - pathogenesis and treatment. Nefrologia 2012; 32:432.</a></li><li><a class="nounderline abstract_t">Chonchol M, Linas S. Diagnosis and management of ischemic nephropathy. Clin J Am Soc Nephrol 2006; 1:172.</a></li><li><a class="nounderline abstract_t">Textor SC, Wilcox CS. Ischemic nephropathy/azotemic renovascular disease. Semin Nephrol 2000; 20:489.</a></li><li><a class="nounderline abstract_t">Gloviczki ML, Glockner JF, Lerman LO, et al. Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis. Hypertension 2010; 55:961.</a></li><li><a class="nounderline abstract_t">ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361:1953.</a></li><li><a class="nounderline abstract_t">Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014; 370:13.</a></li><li><a class="nounderline abstract_t">Textor SC, Novick AC, Tarazi RC, et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985; 102:308.</a></li><li><a class="nounderline abstract_t">Imanishi M, Akabane S, Takamiya M, et al. Critical degree of renal arterial stenosis that causes hypertension in dogs. Angiology 1992; 43:833.</a></li><li><a class="nounderline abstract_t">Gloviczki ML, Glockner JF, Crane JA, et al. Blood oxygen level-dependent magnetic resonance imaging identifies cortical hypoxia in severe renovascular disease. Hypertension 2011; 58:1066.</a></li><li><a class="nounderline abstract_t">Abumoawad A, Saad A, Ferguson CM, et al. Tissue hypoxia, inflammation, and loss of glomerular filtration rate in human atherosclerotic renovascular disease. Kidney Int 2019; 95:948.</a></li><li><a class="nounderline abstract_t">Chade AR, Rodriguez-Porcel M, Grande JP, et al. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 2002; 106:1165.</a></li><li><a class="nounderline abstract_t">Herrmann SM, Saad A, Eirin A, et al. Differences in GFR and Tissue Oxygenation, and Interactions between Stenotic and Contralateral Kidneys in Unilateral Atherosclerotic Renovascular Disease. Clin J Am Soc Nephrol 2016; 11:458.</a></li><li><a class="nounderline abstract_t">Keddis MT, Garovic VD, Bailey KR, et al. Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant 2010; 25:3615.</a></li><li><a class="nounderline abstract_t">Greco BA, Breyer JA. Atherosclerotic ischemic renal disease. Am J Kidney Dis 1997; 29:167.</a></li><li><a class="nounderline abstract_t">Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med 1993; 118:712.</a></li><li><a class="nounderline abstract_t">Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344:431.</a></li><li><a class="nounderline abstract_t">Fatica RA, Port FK, Young EW. Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States. Am J Kidney Dis 2001; 37:1184.</a></li><li><a class="nounderline abstract_t">Valderrábano F, Berthoux FC, Jones EH, Mehls O. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant 1996; 11 Suppl 1:2.</a></li><li><a class="nounderline abstract_t">Korsakas S, Mohaupt MG, Dinkel HP, et al. Delay of dialysis in end-stage renal failure: prospective study on percutaneous renal artery interventions. Kidney Int 2004; 65:251.</a></li><li><a class="nounderline abstract_t">Textor SC, Wilcox CS. Renal artery stenosis: a common, treatable cause of renal failure? Annu Rev Med 2001; 52:421.</a></li><li><a class="nounderline abstract_t">Scoble JE, Hamilton G. Atherosclerotic renovascular disease. BMJ 1990; 300:1670.</a></li><li><a class="nounderline abstract_t">Appel RG, Bleyer AJ, Reavis S, Hansen KJ. Renovascular disease in older patients beginning renal replacement therapy. Kidney Int 1995; 48:171.</a></li><li><a class="nounderline abstract_t">Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. Am J Kidney Dis 1994; 24:622.</a></li><li><a class="nounderline abstract_t">van Ampting JM, Penne EL, Beek FJ, et al. Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 2003; 18:1147.</a></li><li><a class="nounderline abstract_t">Leertouwer TC, Pattynama PM, van den Berg-Huysmans A. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? Kidney Int 2001; 59:1480.</a></li><li><a class="nounderline abstract_t">Baboolal K, Evans C, Moore RH. Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease. Am J Kidney Dis 1998; 31:971.</a></li><li><a class="nounderline abstract_t">Bax L, Woittiez AJ, Kouwenberg HJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009; 150:840.</a></li><li><a class="nounderline abstract_t">Oskin TC, Hansen KJ, Deitch JS, et al. Chronic renal artery occlusion: nephrectomy versus revascularization. J Vasc Surg 1999; 29:140.</a></li><li><a class="nounderline abstract_t">Sivamurthy N, Surowiec SM, Culakova E, et al. Divergent outcomes after percutaneous therapy for symptomatic renal artery stenosis. J Vasc Surg 2004; 39:565.</a></li><li><a class="nounderline abstract_t">Ritchie J, Green D, Chrysochou C, et al. High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization. Am J Kidney Dis 2014; 63:186.</a></li><li><a class="nounderline abstract_t">Kalra PA, Chrysochou C, Green D, et al. The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease. Catheter Cardiovasc Interv 2010; 75:1.</a></li><li><a class="nounderline abstract_t">Textor SC. Attending rounds: a patient with accelerated hypertension and an atrophic kidney. Clin J Am Soc Nephrol 2014; 9:1117.</a></li><li><a class="nounderline abstract_t">Modrall JG, Trimmer C, Tsai S, et al. Renal Salvage with Renal Artery Stenting Improves Long-term Survival. Ann Vasc Surg 2017; 45:106.</a></li><li><a class="nounderline abstract_t">Hadj-Abdelkader M, Alphonse JC, Ravel A, et al. [Proposal of a clinical prediction score for atheromatous renal artery stenosis]. Arch Mal Coeur Vaiss 2003; 96:784.</a></li><li><a class="nounderline abstract_t">Madder RD, Hickman L, Crimmins GM, et al. Validity of estimated glomerular filtration rates for assessment of baseline and serial renal function in patients with atherosclerotic renal artery stenosis: implications for clinical trials of renal revascularization. Circ Cardiovasc Interv 2011; 4:219.</a></li><li><a class="nounderline abstract_t">Rognant N, Rouvière O, Janier M, et al. Hemodynamic responses to acute and gradual renal artery stenosis in pigs. Am J Hypertens 2010; 23:1216.</a></li><li><a class="nounderline abstract_t">MAY AG, DE WEESE JA, ROB CG. Hemodynamic effects of arterial stenosis. Surgery 1963; 53:513.</a></li><li><a class="nounderline abstract_t">Drieghe B, Madaric J, Sarno G, et al. Assessment of renal artery stenosis: side-by-side comparison of angiography and duplex ultrasound with pressure gradient measurements. Eur Heart J 2008; 29:517.</a></li><li><a class="nounderline abstract_t">De Bruyne B, Manoharan G, Pijls NH, et al. Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol 2006; 48:1851.</a></li><li><a class="nounderline abstract_t">Radermacher J, Ellis S, Haller H. Renal resistance index and progression of renal disease. Hypertension 2002; 39:699.</a></li><li><a class="nounderline abstract_t">Herrmann SM, Textor SC. Diagnostic criteria for renovascular disease: where are we now? Nephrol Dial Transplant 2012; 27:2657.</a></li><li><a class="nounderline abstract_t">Muray S, Martín M, Amoedo ML, et al. Rapid decline in renal function reflects reversibility and predicts the outcome after angioplasty in renal artery stenosis. Am J Kidney Dis 2002; 39:60.</a></li><li class="breakAll">Novick AC. Patient selection for intervention to preserve renal function in ischemic renal disease. In: Renal Vascular Disease, Novick AC, Scoble J, Hamilton G (Eds), W.B. Saunders Co, LTD, London 1996. p.323.</li><li><a class="nounderline abstract_t">Krishnamurthi V, Novick AC, Myles JL. Atheroembolic renal disease: effect on morbidity and survival after revascularization for atherosclerotic renal artery stenosis. J Urol 1999; 161:1093.</a></li><li><a class="nounderline abstract_t">Cheung CM, Shurrab AE, Buckley DL, et al. MR-derived renal morphology and renal function in patients with atherosclerotic renovascular disease. Kidney Int 2006; 69:715.</a></li><li><a class="nounderline abstract_t">Safian RD, Madder RD. Refining the approach to renal artery revascularization. JACC Cardiovasc Interv 2009; 2:161.</a></li><li><a class="nounderline abstract_t">Afarideh M, Zhang X, Ferguson CM, et al. Peristenotic Collateral Circulation in Atherosclerotic Renovascular Disease: Association With Kidney Function and Response to Treatment. Hypertension 2020; 76:497.</a></li></ol></div><div id="topicVersionRevision">Topic 3841 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34384806" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23151953" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Percutaneous revascularization for ischemic nephropathy: the past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806277" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ischemic nephropathy - pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699206" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and management of ischemic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11022902" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ischemic nephropathy/azotemic renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194303" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19907042" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Revascularization versus medical therapy for renal-artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24245566" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Stenting and medical therapy for atherosclerotic renal-artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3970470" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1476271" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Critical degree of renal arterial stenosis that causes hypertension in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22042812" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Blood oxygen level-dependent magnetic resonance imaging identifies cortical hypoxia in severe renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30904069" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tissue hypoxia, inflammation, and loss of glomerular filtration rate in human atherosclerotic renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196346" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Distinct renal injury in early atherosclerosis and renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26787779" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Differences in GFR and Tissue Oxygenation, and Interactions between Stenotic and Contralateral Kidneys in Unilateral Atherosclerotic Renovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20501460" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9016887" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Atherosclerotic ischemic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8460859" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Atherosclerotic renovascular disease and progressive renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172181" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal-artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11382687" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Incidence trends and mortality in end-stage renal disease attributed to renovascular disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8735560" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675057" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Delay of dialysis in end-stage renal failure: prospective study on percutaneous renal artery interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160787" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Renal artery stenosis: a common, treatable cause of renal failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202443" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Atherosclerotic renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7564074" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Renovascular disease in older patients beginning renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7942820" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748348" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260411" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Incidental renal artery stenosis in peripheral vascular disease: a case for treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9631841" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414832" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9882798" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chronic renal artery occlusion: nephrectomy versus revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981450" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Divergent outcomes after percutaneous therapy for symptomatic renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24074824" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19937777" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24408123" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Attending rounds: a patient with accelerated hypertension and an atrophic kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28602899" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Renal Salvage with Renal Artery Stenting Improves Long-term Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12945224" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : [Proposal of a clinical prediction score for atheromatous renal artery stenosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21521835" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Validity of estimated glomerular filtration rates for assessment of baseline and serial renal function in patients with atherosclerotic renal artery stenosis: implications for clinical trials of renal revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634798" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hemodynamic responses to acute and gradual renal artery stenosis in pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13934072" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hemodynamic effects of arterial stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18276621" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Assessment of renal artery stenosis: side-by-side comparison of angiography and duplex ultrasound with pressure gradient measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17084261" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment of renal artery stenosis severity by pressure gradient measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11882634" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Renal resistance index and progression of renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22802581" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Diagnostic criteria for renovascular disease: where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11774103" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rapid decline in renal function reflects reversibility and predicts the outcome after angioplasty in renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11774103" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rapid decline in renal function reflects reversibility and predicts the outcome after angioplasty in renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10081845" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Atheroembolic renal disease: effect on morbidity and survival after revascularization for atherosclerotic renal artery stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16395249" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : MR-derived renal morphology and renal function in patients with atherosclerotic renovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463421" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Refining the approach to renal artery revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32507040" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Peristenotic Collateral Circulation in Atherosclerotic Renovascular Disease: Association With Kidney Function and Response to Treatment.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
